Regret Emotion After Thyroidectomy in Low-Risk Papillary Thyroid Cancer
Monitoring and Timely Intervention of Regret Emotion After Thyroidectomy in Low-Risk Papillary Thyroid Cancer Patients: A Multicenter, Randomized, Controlled Trial
1 other identifier
interventional
600
1 country
1
Brief Summary
This randomized, active-controlled, non-inferiority trial is scheduled to begin in May 2025 and will continue until June 2027. Inclusion criteria: (1) Patients with low-risk papillary thyroid cancer without lymph node metastasis who have undergone thyroid surgery (including both laparoscopic and open surgery) at the Department of Thyroid Surgery, West China Hospital, Sichuan University, (2) Aged between 18 and 90 years, (3) Chinese-speaking, (4) Capable of completing questionnaires and using a mobile phone and internet for intervention purposes, (5) No history of psychiatric disorders or use of psychotropic medications, (6) Voluntary participation and signing of an informed consent form. Exclusion criteria: (1) Patients with cervical lymph node metastasis, (2) Incomplete baseline data, (3) Uncontrolled chronic diseases, (4) Patients with other cancers. Online outpatient follow-up will be conducted by doctors from the Department of Thyroid Surgery at West China Hospital. One study participant will contact the patient, introduce the study, and obtain the informed consent form from willing participants. The research team members responsible for patient contact, registration, and randomization include the principal investigator, study coordinator, and specially trained research assistants. The management of the intervention group patients will be carried out by doctors from the corresponding departments. According to the protocol, patients assigned to online visits will switch to offline visits and exit the clinical trial under the following circumstances: (1) unresolved technical issues, (2) inability to perform a comprehensive assessment, (3) patient request for withdrawal. Other cross-cutting reasons include patient requests and scheduling conflicts. Baseline data (including age, gender, ethnicity, address, occupation), tumor-related information (including tumor histology, maximum tumor diameter, capsular invasion status, number of lymph node metastases), and surgical method will be collected from the hospital's information department. Participants will be given the DRS scale upon discharge and every two months thereafter to assess their regret status. For patients with high regret (DRS score \>25), a QoL scale will be further distributed to collect information about their quality of life. The REDCap randomization module will be used, and block randomization will be computer-generated with block sizes of 6 and 9, in a 1:1 ratio, to allocate patients to either the intervention or control group. The allocation sequence will be concealed, and the randomized results will be extracted by an independent data collection team. If intervention group patients need to complete the QoL scale, after completion, the doctor from the department corresponding to the factor with the highest score (i.e., the factor most closely related to the patient's regret state) will receive an SMS notification and will be required to contact the patient by phone or SMS within 24 hours to provide the intervention. If contact is not established within 24 hours of the intervention phase, the research participant will call the patient up to two times to clarify the reason.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started May 2025
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 27, 2025
CompletedFirst Posted
Study publicly available on registry
February 3, 2025
CompletedStudy Start
First participant enrolled
May 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 30, 2027
February 3, 2025
January 1, 2025
2 years
January 27, 2025
January 27, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Clarifying the impact of immediate intervention on patients' postoperative regret psychology.
Over a 12-month period after the start of the study, observe the declining trend of regret scores in patients who received immediate intervention compared to the control group.
From enrollment to the end of follow-up at 12 months
Secondary Outcomes (1)
Main Factors Affecting Postoperative Regret in Low-Risk PTC Patients
From enrollment to the end of follow-up at 12 months
Study Arms (2)
Intervening in patients with postoperative regret emotion.
EXPERIMENTALFor the worst postoperative quality of life factors reported by patients, specialized doctors will provide immediate guidance and management via SMS or phone.
Only the patients' postoperative regret levels and quality of life scores will be collected.
NO INTERVENTIONOnly the patients' postoperative regret levels and quality of life scores will be collected, without any additional interventions.
Interventions
Immediate intervention of the major impaired quality of life factors postoperatively to reduce patients' postoperative regret.
Eligibility Criteria
You may qualify if:
- Patients with low-risk papillary thyroid cancer without lymph node metastasis who have undergone thyroid surgery,
- Aged between 18 and 90 years,
- Chinese-speaking,
- Capable of completing questionnaires and using a mobile phone and internet for intervention purposes,
- No history of psychiatric disorders or use of psychotropic medications,
- Voluntary participation and signing of an informed consent form.
You may not qualify if:
- Patients with cervical lymph node metastasis,
- Incomplete baseline data,
- Uncontrolled chronic diseases,
- Patients with other cancers.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
West China Hospital
Chengdu, Sichuan, 610041, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Dr
Study Record Dates
First Submitted
January 27, 2025
First Posted
February 3, 2025
Study Start
May 1, 2025
Primary Completion (Estimated)
May 1, 2027
Study Completion (Estimated)
May 30, 2027
Last Updated
February 3, 2025
Record last verified: 2025-01